5-ala
Brain Tumor, Primary
Constantinos HadjipanayisSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Brain Tumor, Primary cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-demethyl-4-cholestryloxycarbonylpenclomedine DEKK-TEC, Inc. | Phase 2 | B |
Rvp-001 Reveal Pharmaceuticals Inc. | Phase 2 | B |
Entrectinib Hoffmann-La Roche | Phase 2 | CCC |
Capecitabine Northwell Health | Phase 1/2 | CCC |
(+)-VINCRISTINE H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
View all 28 →
Same molecule, other indications
5-ala is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →